2型糖尿病患者接种重组CHO细胞乙型肝炎疫苗的免疫原性观察  

Immunogenicity of recombinant CHO cell-based hepatitis B vaccine in patients with type 2 diabetes

作　　者：朱中奎[1] 申璐 唐万琴[1] 刘华先 于扬 肖辉 顾维 邓方斌 王锦涛 汤奋扬[2] 解燕[1] Zhu Zhongkui;Shen Lu;Tang Wanqin;Liu Huaxian;Yu Yang;Xiao Hui;Gu Wei;Deng Fangbin;Wang Jintao;Tang Fenyang;Xie Yan(Taizhou Center for Disease Control and Prevention,Taizhou 225300,Jiangsu,China;Jiangsu Provincial Center for Disease Control and Prevention,Nanjing 210009,Jiangsu,China)

机构地区：[1]泰州市疾病预防控制中心,江苏泰州225300 [2]江苏省疾病预防控制中心,江苏南京210009

出　　处：《中国疫苗和免疫》2023年第6期620-623,共4页Chinese Journal of Vaccines and Immunization

基　　金：中国乙肝防控科研基金资助课题(YGFK20210033)。

摘　　要：目的 探讨2型糖尿病(Diabetes mellitus,DM)患者接种重组CHO细胞乙型肝炎(乙肝)疫苗(Hepatitis B vaccine,HepB)的免疫原性。方法 在泰州市12个社区卫生服务中心招募乙肝五项血清标志物均阴性且无HepB接种史的2型DM患者(DM组)以及健康人群(对照组),按照0-1-6月免疫程序接种20μg重组CHO细胞HepB,采用电化学发光法定量检测免疫后4-6周乙肝表面抗体(Hepatitis B surface antibody,HBsAb),分析抗体阳转率和中位数浓度(Median concentration,MC)。结果 DM组、对照组分别纳入受试者224例、227例,两组受试者HepB全程免疫后HBsAb阳转率分别为91.96%、97.80%(χ~2=7.93,P=0.005),MC分别为539.70 mIU/mL、1 000 mIU/mL(Z=4.78,P<0.001)。结论 2型DM患者接种重组CHO细胞HepB后具有较好的免疫原性,但弱于健康人群。Objective To explore the immunogenicity of recombinant CHO cell-based hepatitis B vaccine(HepB) in patients with type 2 diabetes(DM).Methods We recruited patients with type 2 DM(DM group) and healthy individuals(control group) who were negative to five serum markers of hepatitis B virus and had not received HepB in any of the 12 community health service centers of Taizhou.Subjects in both groups received 20 μg recombinant CHO cell-based HepB in a 0-1-6-month immunization schedule.We tested sera for hepatitis B surface antibody(HBsAb) 4-6 weeks after vaccination using electrochemiluminescence assay to determine the seroconversion rate and median concentration(MC) of antibody.Results We enrolled 224 subjects into the DM group and 227 into the control group.The HBsAb conversion rate after HepB vaccination was 91.96% in the DM group and 97.80% in the control group(χ~2=7.93,P=0.005),with MCs being 539.70 mIU/mL and 1 000 mIU/mL(Z=4.78,P<0.001),respectively.Conclusions The immunogenicity of recombinant CHO cell-based HepB was high among patients with type 2 DM but was lower than among healthy people.

关 键 词：重组CHO细胞乙型肝炎疫苗 乙型肝炎表面抗体 免疫原性 2型糖尿病 

分 类 号：R186[医药卫生—流行病学] R512.62[医药卫生—公共卫生与预防医学]